2018 American Transplant Congress
Kidney Transplant Outcomes in Patients with CPRA Values > 98% after Implementation of the New OPTN/UNOS Kidney Allocation System (KAS): A Single Center Study Update
Background: Sensitized patients in the past have had prolonged waiting times and greater incidence of death while on the waiting list. On December 4, 2014,…2018 American Transplant Congress
Complement Activating HLA Class 2 Antibodies Are Associated with Poor Renal Allograft Survival; Multicentre Study
IntroductionRole of Class I and II pre-formed complement activating antibodies on renal outcomes is not well defined. In this multicentre study, we looked at the…2018 American Transplant Congress
Ischemia Reperfusion Injury & Risk for Antibody Mediated Rejection (ABMR) in HLA Sensitized Patients Treated with C1 Esterase Inhibitor (C1INH)
Introduction: Ischemia reperfusion injury (IRI) contributes to delayed graft function (DGF). IRI/DGF in HLA-sensitized (HS) patients likely activates innate and memory injury pathways that may…2018 American Transplant Congress
Identifying Patients with CPRA>99.95% Likely to Be Offered Deceased Donor Kidneys
Emory Transplant Center, Atlanta, GA.
The implementation of the new kidney allocation system and priority of kidneys for cPRA=100% subjects revealed a hierarchy difference in allocation to patients with cPRA=99.45%-100%.…2018 American Transplant Congress
Inferior Patient and Graft Survival in Highly Sensitized Adult Kidney Transplant Recipients with a Prior Transplant Compared to Pediatric Kidney Transplant Recipients: An Analysis of OPTN Data
Under the current kidney allocation system (KAS), pediatric (PED) renal transplant (RTx) candidates have a priority to kidneys from KDPI <35% donors. However, that excludes…2018 American Transplant Congress
CTLA4-Ig and Bortezomib Successfully Reverses Established DSA Responses in Allograft-Sensitized Recipients
Background: Sensitized recipients have lower rates of transplantation and poorer outcomes. We and others have reported that the delayed administration of CTLA4-Ig can disrupt fully-established…2018 American Transplant Congress
Tocilizumab Stabilizes Renal Function in Kidney Transplant Recipients with Chronic Active Antibody Mediated Rejection (CAAMR)
Columbia University, New York.
INTRO: CAAMR after kidney transplantation (KTx) is associated with rates of allograft failure approaching 50% at 2 years from injury involving T cells, B cells,…2018 American Transplant Congress
Extended Experience Using Tocilizumab (Anti-IL6R, TCZ) for the Treatment of Chronic Antibody Mediated Rejection (CABMR)
Introduction: Disruption of the IL-6/IL-6R pathways may have benefits in treating allograft rejection. We reported our experience with anti-IL-6R (TCZ) as a treatment for CABMR…2018 American Transplant Congress
A Follow-Up Report on the Use of IVIG+Rituximab to Reduce Donor Specific Antibodies and Improve Transplant Rates in Highly-Sensitized Patients Awaiting Deceased Donor Kidney Transplantation
Medicine/Nephrology, Cedars Sinai Medical Center, Los Angeles, CA.
Introduction: Desensitization (DES) with IVIG/rituximab is associated with a reduction in donor specific antibodies (DSA), improved transplant rates and outcomes in highly-sensitized (HS) patients. We…2018 American Transplant Congress
Impact of the New KAS on Transplant Rates in Highly-HLA Sensitized (HS) Patients after Desenstization (DES): 3yrs Post Implementation
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA.
Introduction: The KAS aims to increase equity in organ allocation for broadly sensitized (HS) patients, especially (CPRA 99-100%). Coupling desensitization (DES) + KAS likely will…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 15
- Next Page »